1.35
+0.02(+1.50%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.33 |
| Day High | 1.36 |
| Day Low | 1.33 |
| 52-Week High | 22.5 |
| 52-Week Low | 0.92 |
| Volume | 848,585 |
| Average Volume | 491,996 |
| Market Cap | 81.16M |
| PE | -0.41 |
| EPS | -3.27 |
| Moving Average 50 Days | 1.24 |
| Moving Average 200 Days | 5.52 |
| Change | 0.02 |
If you invested $1000 in IGM Biosciences, Inc. (IGMS) since IPO date, it would be worth $55.56 as of July 09, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of IGM Biosciences, Inc. (IGMS) shares 5 years ago, it would be worth $18.84 as of July 09, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jul 01, 2025 12:58 PM GMT
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
GlobeNewswire Inc.
Jan 09, 2025 6:00 PM GMT
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 202
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 08, 2024 12:00 PM GMT
– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by yea